1. Home
  2. FNLC vs RCEL Comparison

FNLC vs RCEL Comparison

Compare FNLC & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Bancorp Inc  (ME)

FNLC

First Bancorp Inc (ME)

HOLD

Current Price

$26.85

Market Cap

288.7M

Sector

Finance

ML Signal

HOLD

Logo Avita Medical Inc.

RCEL

Avita Medical Inc.

HOLD

Current Price

$3.44

Market Cap

102.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FNLC
RCEL
Founded
1864
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
288.7M
102.5M
IPO Year
1999
N/A

Fundamental Metrics

Financial Performance
Metric
FNLC
RCEL
Price
$26.85
$3.44
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$11.75
AVG Volume (30 Days)
20.3K
200.7K
Earning Date
01-21-2026
02-12-2026
Dividend Yield
5.51%
N/A
EPS Growth
18.07
N/A
EPS
2.81
N/A
Revenue
$88,119,000.00
$72,401,000.00
Revenue This Year
N/A
$13.12
Revenue Next Year
N/A
$27.56
P/E Ratio
$9.55
N/A
Revenue Growth
12.70
20.59
52 Week Low
$22.11
$3.25
52 Week High
$28.60
$14.16

Technical Indicators

Market Signals
Indicator
FNLC
RCEL
Relative Strength Index (RSI) 51.35 42.88
Support Level $28.05 $3.37
Resistance Level $28.60 $3.71
Average True Range (ATR) 0.51 0.18
MACD -0.10 0.02
Stochastic Oscillator 34.21 41.30

Price Performance

Historical Comparison
FNLC
RCEL

About FNLC First Bancorp Inc (ME)

First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.

About RCEL Avita Medical Inc.

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.

Share on Social Networks: